In year 3 of the pandemic, a new Covid-19 biotech takes flight with an antibody combo and Takeda's ex-vaccines chief at the helm

Kyle LaHucik

Senior Reporter

Year three of the Covid-19 pandemic just began, but this far in, Omega Funds thinks it’s not too late to launch a biotech to fight SARS-CoV-2 just as another subvariant takes flight and cases rise in various regions.

The prolific biotech incubator poached Takeda’s former vaccines leader Rajeev Venkayya and inked research agreements with Swiss universities to create Aerium Therapeutics, named after the Latin word for airborne. With the cover now off, Aerium can put to work two monoclonal antibodies that it says have shown neutralization against Omicron and its subvariants in preclinical testing that is yet to be peer reviewed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

In year 3 of the pandemic, a new Covid-19 biotech takes flight with an antibody combo and Takeda's ex-vaccines chief at the helm

Kyle LaHucik

Senior Reporter

Unlock this article instantly by becoming a free subscriber.

J&J's AI head jumps to Recursion; Doug Williams resigns as Sana's R&D chief

Rare neuro disorder offers new area for competition, analysts say: #AAN24

Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal

CSL Vifor proposes a marketing campaign to settle European Commission investigation

Takeda wins label expansion for subcutaneous Entyvio, creating 'flexibility' for Crohn's patients

Senators want to know more on why Novo is discontinuing its insulin Levemir

In year 3 of the pan­dem­ic, a new Covid-19 biotech takes flight with an an­ti­body com­bo and Takeda's ex-vac­cines chief at the helm

Kyle LaHucik

Senior Reporter

Unlock this article instantly by becoming a free subscriber.

more like this

J&J's AI head jumps to Re­cur­sion; Doug Williams re­signs as Sana's R&D chief

Rare neu­ro dis­or­der of­fers new area for com­pe­ti­tion, an­a­lysts say: #AAN24

Ver­tex, Alpine’s IgAN drug has Hu­mi­ra-like po­ten­tial. But not all in­di­ca­tions are cre­at­ed equal

CSL Vi­for pro­pos­es a mar­ket­ing cam­paign to set­tle Eu­ro­pean Com­mis­sion in­ves­ti­ga­tion

Take­da wins la­bel ex­pan­sion for sub­cu­ta­neous En­tyvio, cre­at­ing 'flex­i­bil­i­ty' for Crohn's pa­tients

Sen­a­tors want to know more on why No­vo is dis­con­tin­u­ing its in­sulin Lev­emir

In year 3 of the pandemic, a new Covid-19 biotech takes flight with an antibody combo and Takeda's ex-vaccines chief at the helm

J&J's AI head jumps to Recursion; Doug Williams resigns as Sana's R&D chief

Rare neuro disorder offers new area for competition, analysts say: #AAN24

Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal

CSL Vifor proposes a marketing campaign to settle European Commission investigation

Takeda wins label expansion for subcutaneous Entyvio, creating 'flexibility' for Crohn's patients

Senators want to know more on why Novo is discontinuing its insulin Levemir